SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Loss Swing To C¥270 Million Tests Bullish Growth Narratives
CStone Pharmaceuticals (SEHK:2616) has just posted its FY 2025 first half numbers, with revenue of C¥49.5 million and basic EPS showing a loss of C¥0.21, while trailing 12 month figures sit at C¥269.6 million of revenue and a loss of C¥0.31 in basic EPS. Over recent periods the company has seen revenue move from C¥254.2 million in the first half of 2024 to C¥153.0 million in the second half of 2024 and then to C¥49.5 million in the first half of 2025, with EPS shifting from a profit of C¥0.01...